The Next Pharma Gold Rush

GLP-1 is transitioning from an innovation goldmine to a manufacturing battleground. Apotex’s tentative US FDA approval for generic semaglutide with India’s Orbicular Pharma is not a regulatory milestone but a signal that the science has already been cracked. What remains is timing.As patents begin to open up over the next few years, this $100B+ market will shift from high-margin innovation to scale-driven competition. And unlike traditional generics, this will be defined by peptide capability, regulatory precision, and global partnerships.The focus is shifting from the innovators to the ones who can execute at scale because in every pharma cycle, a few companies dominate.Who will that be this time? This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com